eligibility_summary
Eligibility: Adults 18–70 with NK/T‑cell lymphoma or NK cell leukemia that is relapsed/refractory or after HSCT/cellular therapy failure, lacking options or choosing anti‑CD56 CAR‑T, measurable disease, adequate organs (ALT/AST <3×ULN, bilirubin ≤34.2 μmol/L, creatinine <220 μmol/L, SpO2 ≥95%, LVEF ≥40%), ECOG ≤2, survival ≥3 mo, consent, no anticancer therapy ≤4 wks, good venous access. Exclude: pregnancy/no contraception, active infection (HBV/HCV/HIV), autoimmune/immunodeficiency, biologic allergy, recent trial (≤6 wks) or steroids (≤4 wks), serious psych/substance issues, other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Anti‑CD56 CAR‑T cells (autologous, gene‑modified T‑cell therapy, biological) given after fludarabine/cyclophosphamide lymphodepletion. Mechanism: CAR uses an anti‑CD56 (NCAM1) scFv to direct T‑cell activation and cytotoxicity against CD56+ tumor cells, the construct incorporates PD‑1 signal conversion (checkpoint “switch”) to overcome PD‑1/PD‑L1–mediated inhibition and enhance killing versus conventional second‑generation CAR‑T. Targets: CD56/NCAM1 on malignant NK/T‑cell lymphoma and NK‑cell leukemia cells, modulation of the PD‑1/PD‑L1 checkpoint pathway, effector is patient T‑cell cytotoxic machinery.